How Does Leqembi Differ from Other FDA-Approved Alzheimer's Medications?

A commonly asked question regarding Leqmebi is: How does it differ from other Alzheimer's medications approved by the FDA like Aricept, Exelon, and Razadyne?

‍

The short answer is Leqembi targets what is accepted as one of the hallmark underlying pathologies of Alzheimer's disease — beta-amyloid. Its main aim is to slow down the progression of the disease by targeting this issue. Other medications like Aricept, Exelon, and Razadyne are all about symptom management and mainly help with memory and thinking problems (cognitive symptoms). However, they are not actually slowing down the disease progression of Alzheimer's. The disease is still progressing in the background. Now, Leqembi does not actually make any claims to improve or even stabilize cognitive symptoms and instead focuses primarily on slowing down the worsening of the disease itself. And in fact, over 50 % of their participants in their phase 3 trials were actually taking another Alzheimer's medication.

‍

So here's the breakdown: 

Leqembi = targeting disease pathology (beta-amyloid in the brain) to slow down the progression of Azheimer’s disease.

Aricept, Exelon, Razadyne, Namenda, and Namzaric = symptom management by allowing the brain to work better with what’s going on. The disease is still progressing behind the scenes.

‍

There are many other differences between Leqemebi and other FDA approved medications, however, this is one of the biggest differences.

‍

Please note: Bambu Care has no association with Leqembi and the information provided is for educational and informational purposes only. Talk to you or your partner’s doctor for specific advice and recommendations regarding Leqembi.